Safety and efficacy of atezolizumab plus bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma undergoing dialysis: a case series-Reference-Cited by-同舟云学术

Safety and efficacy of atezolizumab plus bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma undergoing dialysis: a case series

Published:2024-03-19 Issue:3 Volume:17 Page:515-522
ISSN:1865-7257
Container-title:Clinical Journal of Gastroenterology
language:en
Short-container-title:Clin J Gastroenterol

Author:

Sakaguchi Koki,Satoh Tatsunori^ORCID,Kawaguchi Shinya,Aoyama Takuya,Asahara Kazuhisa,Endo Shinya,Shirane Naofumi,Kanemoto Hideyuki,Oba Noriyuki,Ohno Kazuya

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12328-024-01946-7.pdf

Reference25 articles.

1. Hiyamuta H, Yamada S, Taniguchi M, et al. Causes of death in patients undergoing maintenance hemodialysis in Japan: 10-year outcomes of the Q-Cohort Study. Clin Exp Nephrol. 2021;25:1121–30.

2. Hasegawa K, Takemura N, Yamashita T, et al. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines). Hepatol Res. 2023;53:383–90.

3. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

4. Panoilia E, Schindler E, Samantas E, et al. A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. Cancer Chemother Pharmacol. 2015;75:791–803.

5. Klajer E, Garnier L, Goujon M, et al. Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: a systemic review. Semin Oncol. 2020;47:103–16.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atezolizumab/Bevacizumab;Reactions Weekly;2024-08-03